A longitudinal seroprevalence study in a large cohort of working adults reveals that neutralising SARS-CoV-2 RBD-specific antibodies persist for at least six months independent of the severity of symptoms. Preprint

Nav

General Info

Geography

Austria (AUT)

Wien

Coverage type

Subnational

Time period covered

01/2020 - 12/2020

Data type

Scientific literature

Keywords

Blood tests, COVID-19, Disease outbreaks, Infectious diseases, Medical tests, Symptoms

Citation

Authors

Wagner A, Guzek A, Ruff J, Jasinska J, Scheikl U, Zwazl I, Kundi M, Stockinger H, Farcet MR, Kreil TR, Hoeltl E, Wiedermann U

Journal

medRxiv

Publication year

2020

Suggested citation

Wagner A, Guzek A, Ruff J, Jasinska J, Scheikl U, Zwazl I, Kundi M, Stockinger H, Farcet MR, Kreil TR, Hoeltl E, Wiedermann U. A longitudinal seroprevalence study in a large cohort of working adults reveals that neutralising SARS-CoV-2 RBD-specific antibodies persist for at least six months independent of the severity of symptoms. Preprint. medRxiv. 2020.

GHDx Entry last modified on: Jun 18, 2021

Header sites

Search form

Main menu

A longitudinal seroprevalence study in a large cohort of working adults reveals that neutralising SARS-CoV-2 RBD-specific antibodies persist for at least six months independent of the severity of symptoms. Preprint

Nav